双重生物治疗公司在香港股市首次亮相, 股价升130%, Duality Biotherapeutics debuts on Hong Kong stock market, shares surge 130%, raising $213M.

专注于癌症和自身免疫性疾病治疗的中国生物技术公司Duality Biotherapeutics在2025年4月15日在香港首次亮相时,其股价升了130%. Duality Biotherapeutics, a Chinese biotech company focusing on cancer and autoimmune disease treatments, saw its shares skyrocket by 130% on its debut in Hong Kong on April 15, 2025. 该公司在最初的公开发行中筹集到2.13亿港元,售出1 733万股,每股94.60港元。 The company raised $213 million in its initial public offering, selling 17.33 million shares at HK$94.60 each. 尽管全球市场波动,但Duality吸引了个人和机构投资者的大量兴趣,股票申请量达到报价的115倍. Despite global market volatility, Duality attracted significant interest from both retail and institutional investors, with applications for shares reaching 115 times the offer. 取得成功的部分原因是,由于许可证协议,该公司的产品基本上不受美国进口关税的约束。 The success is partly attributed to the company's products being largely exempt from US import tariffs due to licensing agreements.